US Stock Market Move | NVIDIA Corporation-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, rises over 11% after the open.

On Thursday, Iambic Therapeutics (IAM.US), an AI pharmaceutical company backed by NVIDIA Corporation, debuted on Nasdaq. As of press time, the stock rose over 11% to $17.77, triggering a exchange circuit breaker. The IPO price was $16. Iambic Therapeutics is a clinical-stage biotechnology company that combines proprietary AI models with automated high-throughput chemistry and biology to design small molecule drugs. The platform operates a closed-loop process: its models propose compound designs, and Siasun Robot&Automation laboratories synthesize and test hundreds of compounds per project each week, with the resulting data used to retrain the models. Its lead candidate, IAM1363, is a selective, blood-brain barrier-penetrant HER2 inhibitor currently in Phase 1/1b clinical trials for HER2-altered solid tumors, with a registrational trial potentially starting as early as 2027; two other preclinical programs targeting KIF18A and CDK2/4 are planned for IND submissions in the fourth quarter. To date, Iambic Therapeutics has generated revenue through collaborations with AbbVie (ABBV.US), Takeda Pharmaceutical Co. Ltd. Sponsored ADR (TAK.US), Bayer (BAYRY.US), and others.